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Objective: To evaluate the effects of postoperative anticancer chemo-
therapy for small cell lung cancer on LCNEC.
Methods: Twenty-four patients who had undergone resection of 
LCNEC in our hospital between 1986 and 2004 were classiﬁed, accord-
ing to the presence or absence of postoperative adjuvant chemotherapy 
and to its regimen, into group A which received two or more courses 
of a platinum-based regimen with VP-16 or CPT-11 for small cell lung 
cancer, group B which received other regimens, and group C which re-
ceived no postoperative adjuvant chemotherapy, and evaluated in terms 
of 5-year recurrence-free survival and 5-year survival rates.
Results: The subjects consisted of 24 men and 2 women, with a mean 
age of 68 years, and all were smokers. Six patients had stage I cancer, 4 
stage II cancer, 13 stage III cancer, and 1 stage IV cancer. Six patients 
(25%) belonged to group A, 4 (1 received MVP 2 courses, 1 CAV 1 
courses, and 2 UFT courses) to group B, and 14 to group C. The 5-year 
recurrence-free survival and 5-year survival rates in group A were 50% 
each, whereas all patients in group B died within 2 years, and the 5-
year recurrence-free survival and 5-year survival rates in group C were 
25% and 34%, respectively.
Discussion: No signiﬁcant intergroup differences were observed, be-
cause of the small number of patients studied. However, the prognosis 
in group A was slightly better than that in groups B and C. Since the 
present study evaluated a small number of patients in all stages of can-
cer, the current issue remained unresolved. Therefore, further studies 
are needed in more patients.
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Background: We have reported an efﬁcacy of the combination of 
cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for 
the treatment of previously untreated patients with non-small cell lung 
cancer (NSCLC). Concurrent radiation applied to cisplatin-based che-
motherapy with new anticancer agents is expected for locally advanced 
NSCLC. We evaluated the efﬁcacy and safety of cisplatin and weekly 
docetaxel combined with thoracic radiotherapy for patients with Stage 
III advanced NSCLC. 
Methods: We identiﬁed 34 eligible patients with locally advanced 
NSCLC and good performance status (PS) (ECOG; 0 or 1) who had 
not received prior treatment and who were under 75 years old. Their 
median age was 63 years (range, 45-74 years), 32 patients were male 
(94.1%), two (5.9%) were female, 30 (88.2%) had PS 0, 4 (11.8%) had 
PS 1, 3 had Stage IIIA (8.9%), and 31 had Stage IIIB (91.1%). Tumor 
histology included adenocarcinoma (55.9 %) and epidermoid (41.2 %). 
The patients received intravenous infusions of docetaxel (20 mg/m2, 
days 1, 8, 15) and cisplatin (80mg/m2, day 1) with standard thoracic 
concurrent radiation (60Gy, 2Gy/day).
Result: Grade 3/4 neutropenia was recorded in four patients (12 %), 
but there were no episodes of neutropenic fever. Nonhematologic toxic-
ities were also mild, consisting mainly in grade II anorexia. Esophagitis 
and pulmonary toxicities over Grade 3 were observed in 18 % and 12 
%, respectively. One complete response and 19 partial responses were 
observed and the objective response rate was 59.6 %. The median sur-
vival time was 26.4 months, and the 1-year survival rate was 76.0 %. 
Conclusion: Cisplatin with weekly administration of docetaxel com-
bined with concurrent radiotherapy is a feasible and effective regimen 
against advanced NSCLC.
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Background: In locally advanced non-small cell lung cancer(NSCLC), 
concurrent chemoradiotherapy(CCRT) becomes the leading therapeutic 
modality. But there are still many controversies in the chemotherapeu-
tic regimens and in the radiation methods. 
Materials and Methods: 27 NSCLC patients of clinical stage IIIB, 2 
patients with stage IIIA were enrolled since December 2002. The per-
formance status of ECOG grade 0 or 1 was in 22 patients(75.9%) and 
the others were grade 2. Squamous cell cancer was the most common 
(62%), followed by adenocarcinoma (31%). Cisplatin(30mg/m2) and 
gemcitabine(500mg/m2) were administered every two weeks while 50.4 
Gy(28 fractions) was irradiated on the tumor site. Booster irradiation of 
18 Gy (10 fractions) was administered unless the disease progressed. 
Two or three cycles of consolidation chemotherapy were done with 
gemcitabine(1200mg/m2 1st and 8thday) and cisplatin(60mg/m2) every 
three weeks. 
Results: During CCRT, severe esophagitis(>grade III) was serious 
complication(51.6%), followed by granulocytopenia(72.2%) and 
pneumonitis(20.7%). But they were mostly grade 2 and well managed 
by medical treatments and no patients withheld the treatment. After the 
consolidation chemotherapy, 3 patients(10.3%) had complete remis-
sion, 21 patients (72.4%) showed partial remission, and in 4 patients, 
the disease was stable, and in 1 patients it progressed. 
Median survival time was 16 months( 95% CI;2.4-39.2 months), The 
survival rates in one, two, and three years are 62.7%, 43.9%, 20%, 
respectively. 
Conclusion: The response rate and survival time of biweekly gem-
citabine plus cisplatin chemotherapy with concurrent radiotherapy 
was encouraging in patients with locally advanced NSCLC. However, 
treatment related toxicities were signiﬁcant, thus further modiﬁcation 
of therapy seems to be warranted. 
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Background: The efﬁcacy of Tyrosine Kinake inhibitors (TKIs) of 
EGFR is associated with well characterized mutations on the exons 18, 
19 and 21 of EGFR gene. Less common mutations could be detected in 
these exons but their relationship with the clinical efﬁcacy of TKIs has 
not been established yet. 
Methods: Genomic DNA was extracted from microdissected formalin-
ﬁxed parafﬁn-embeded tumor tissue from 86 pts enrolled in a geﬁtinib 
expanded access program. Exons 18, 19 and 21 were ampliﬁed and 
subjected to direct sequencing. 
Results: Classical EGFR mutations (CM) were detected in 9 (10.4%) 
pts and other mutations variants (MV) in 19 (22%) pts. Eight (42.1%) 
MV were observed in exon 18, 3 (15.8%) in exon 19 and 8 (42.1%) 
in exon 21. Tumor Growth Control (TGC) was achieved in 88.9% 
(3PR and 5SD) pts with CM, 63% (2PR and 10SD) pts with MV and 
in 45.9% (3PR and 25SD) pts with wild type EGFR gene (WT). There 
was no clear association between the presence of EGFR MV and the 
sex, histology or smoking history. The median TTP was 64 weeks 
(range:4-80+), 20 weeks (range:6-140) and 16 weeks (range:4-176+) 
in pts with CM, MV and WT, respectively. Nine (47.3%) pts with 
EGFR MV had a TTP >24 weeks. The median survival was 78 weeks 
(range:5-94+), 70 weeks (range:10-142) and 36 weeks (range:4-176+) 
in pts with CM, MV and WT, respectively. Three patients bearing 
mutations in exons 18, 19, and 21 progressed despite geﬁtinib treat-
ment suggesting that these mutations could be related to resistance to 
geﬁtinib. 
Conclusions: EGFR mutation variants could be associated with 
response or resistance to TKIs but their low incidence requires their 
evaluation in a largest cohort of patients. 
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Background: Surgery improved the results of treatment for stage IIIA 
non small cell lung cancer (NSCLC). However, a signiﬁcant fraction 
of patients after surgical resection die due to local or systemic re-
lapses. Nonetheless, the best adjuvant therapy to improve survival and 
decrease relapse rate remains as an ever controversial issue. There-
fore, we conducted a randomized trial to determine whether or which 
postoperative adjuvant therapy is beneﬁcial in prolonging survival and 
decreasing recurrence in patients with completely resected stage IIIA 
NSCLC. 
Methods: This trial was initiated by the Lung Cancer Research Team 
at Korea Cancer Center Hospital March 1989, and enrollment was 
stopped December 1998. It was designed as a randomized, prospec-
tive three-armed study with surgery only (control group, 55 patients) 
versus surgery plus adjuvant radiotherapy (study group I, 56 patients) 
and surgery plus adjuvant MVP (mitomycin C, vinblastin and cisplatin) 
chemotherapy (study group II, 53 patients). 
Results: Data for all the patients were complete after long-term follow-
up. Thirty-eight patients in the control group, thirty patients in the study 
group I and twenty-nine patients in the study group II experienced 
tumor recurrence during follow-up. The median times of disease-free 
were 16.3 months (control group), 35.3 months (study group I), and 
36.6 months (study group II). The 5-year disease-free survival rates 
were 28.9%, 41.1% and 49.4%, respectively (p=0.10, log-rank test). 
Even though there was no signiﬁcant difference statistically, log-rank 
test for trend of disease-free survival was signiﬁcant (p=0.039). Only 
twelve patients (control group), nine patients (study group I), and 
sixteen patients (study group II) were survived until the end of follow-
up. The median survival times were 31.8 months (control group), 27.0 
months (study group I), and 55.7 months (study group II). The 5-year 
overall survival rates were 29.8 %, 37.5% and 48.1 %, respectively 
(p=0.22, log-rank test).
Conclusions: Our results suggest that the addition of adjuvant radio-
therapy or adjuvant MVP chemotherapy may not reduce the incidence 
of recurrence and prolong the disease-free or overall survival rates of 
the patients with stage IIIA NSCLC after surgery.
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Aim: Retrospective analysis of treatment with cisplatin/gemcitabine 
followed by cisplatin/etoposide and concurrent thoracic radiotherapy 
(TRT) for patients with irresectable or medically inoperable non-small-
cell lung cancer (NSCLC).
Methods: Stage III NSCLC patients received one course of cisplatin 
(80mg/m2, day 1) and gemcitabine (1250mg/m2, day 1 and 8) followed 
by cisplatin (80mg/m2, day 21 and 42) and etoposide (100mg/m2, days 
21-23 and 42-44). Concurrent TRT commenced on day 22, 5 days/week 
for 5 weeks. National Cancer Institute of Canada grading system v3.0 
was used for evaluation of toxicity. Radiological response was evalu-
ated using RECIST criteria. Patients with potentially resectable stage 
III NSCLC and good performance status underwent mediastinal restag-
ing after 46-50 Gy followed by surgery if no N2-disease or distant 
metastatic disease was found. All others received radiotherapy to a total 
dose of 50-60 Gy.
Results: A total of 57 patients were treated between October 2003 and 
December 2006. Of those, 5 had medically inoperable stage IIA (1) 
and IIB (4), 24 stage IIIA, 25 stage IIIB and 3 patients with stage IV 
NSCLC. Prior treatments for NSCLC in 14 patients included pneu-
monectomy (3), (bi)lobectomy (9), stereotactic radiotherapy (1) and 
chemotherapy (6). During 178 evaluable courses of chemotherapy 
(total 179 courses), grade III/IV anemia was reported in 6 courses 
(3.4%), grade III/IV thrombocytopenia in 22 courses (12.4%) and grade 
III/IV leucocytopenia in 65 courses (36.5%). One patient died of grade 
V febrile neutropenia and one patient died as a result of lung bleeding 
after 6 Gy. Transfusions for anemia were necessary after 12 courses and 
hospitalisation for neutropenic fever in 7 cases. Carboplatin replaced 
